Cancer detection that's as determined as you are.

Mantle cell lymphoma (MCL) is typically an aggressive cancer,1 and treatment has come a long way in recent years. But to make the most of today’s therapies, your doctor needs advanced tools that can detect even the smallest traces of disease. This information can be critical to making important decisions about your care.2

When it comes to treating MCL, your doctor’s ability to detect and monitor these traces of disease may be important for making timely and informed decisions about your treatment plan.3-7

MRD testing helps you and your doctor assess your response to treatment, measure your disease over time, and potentially detect early signs of returning cancer by assessing low levels of disease other tests may miss.3,7,8


  1. Referenced with permission from the NCCN Guidelines for Patients®️ for Mantle Cell Lymphoma, 2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  3. Epstein-Peterson Z, et al. Haematologica. August 31, 2023 [epub ahead of print]. doi: 10.3324/haematol.2023.282898
  1. Wang M, et al. J Clin Oncol. 2023;41(3):555–567.
  2. Phillips T, et al. Blood Adv. 2023;7(16):4518-4527.
  3. Kumar A, et al. Clin Lymphoma Myeloma Leuk. 2021;21(4):230-237.
  4. Rezazadeh A, et al. Clin Lymphoma Myeloma Leuk. 2023;2152-2650.
  5. Kumar A. Paper presented at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 738.